louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04233411: The Bioavailability of Mycoprotein
Official title: The Bioavailability of Mycoprotein
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Availability of Mycoprotein
Lead sponsor: University of Exeter
Sponsor class: OTHER
First posted: 2020-01-18
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: To evaluate the bioavailability of mycoprotein, compared with a reference animal based protein, in a dose-response manner.


Eligibility criteria: Inclusion Criteria:

* Healthy and aged 18-40 y
* BMI between 18 and 30

Exclusion Criteria:

* On medication
* Family history of metabolic disease
* Diagnosed with any metabolic or cardiovascular conditions
* BMI \< 18 or \> 30

Primary outcomes:
measure: Plasma total amino acid concentrations
timeFrame: 4 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Exeter
country: United Kingdom
facility: Sport & Health Sciences
state: Devon
Study officials:
affiliation: University of Exeter, College of Life and Environmental Sciences
name: Benjamin T Wall, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06897111: Implantation of Cartilage Mini-grafts Made From Donor Cells to Treat Chondral Lesions of the Knee
Official title: Implantation of Allogenic Cartilage Mini-grafts: First-In-Human Study for Treating Chondral Lesions of the Knee. Open Cohort, Small Sample Size With 6 Months Follow-Up
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Cartilage Repair
Keywords: Cartilage repair
Lead sponsor: Vanarix SA
Sponsor class: INDUSTRY
First posted: 2025-03-26
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the safety and feasibility of implanting allogeneic cartilage mini-grafts (or allogenic Cartibeads) into cartilage defects in the knee.

Allogeneic Cartibeads are engineered from allogeneic articular chondrocytes (from a donor's cartilage cells). The donor, who in 2022 participated in the Autologous Cartibeads clinical trial (Swissmedic ID 701146), consented to use his leftover cells for production of mini-grafts for other patients in this study. Our patented, standardized methodology allows production of bead-shaped mini-grafts (Allogeneic Cartibeads). These grafts are 1 to 2 mm in diameter and have similar characteristics to native hyaline cartilage.

Allogeneic Cartibeads are implanted into the patient's cartilage defect. Patients are then followed for 6 months for assessment of study endpoints, with safety being the primary outcome.


Eligibility criteria: Key inclusion criteria:

* Symptomatic cartilage lesion(s) of the femorotibial and/or patellofemoral compartments (includes isolated, multiple and kissing lesions)
* Cartilage lesion(s) ≥ 1 cm2 and ≤ 10 cm2
* ICRS grade 3 or 4
* Aged over 18 years

Key exclusion criteria

* Inability to undergo MRI
* Cartilage specific surgery within 6 months from baseline
* Cartilage therapeutic injection within 3 months from baseline
* Chronic inflammatory arthritis and/or infectious arthritis

Primary outcomes:
measure: Safety
timeFrame: From enrolment to the end of follow-up at 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lugano
country: Switzerland
facility: Ente Ospedaliero Cantonale (EOC)
state: Ticino
city: Geneva
country: Switzerland
facility: Center for Sports Medicine and Exercise, Hirslanden Clinique La Colline
city: Geneva
country: Switzerland
facility: Geneva University Hospitals (HUG)
city: Zurich
country: Switzerland
facility: Balgrist University Hospital (BUH)
Study officials:
References:
Clinical trial NCT03166111: Lidocaine In-situ Gel Prior to Intrauterine Device Insertion in Women With no Previous Vaginal Delivery
Official title: Effect of Self-administered Lidocaine In-situ Gel Prior to Intrauterine Device Insertion in Women With no Previous Vaginal Delivery: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Contraception
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-05-24
Enrollment: 216
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Long-acting reversible contraception methods are highly effective methods for reduction of the unplanned pregnancy rate worldwide. The intrauterine device is a single procedure that provides reliable, effective and long term contraception for many women. However, the insertion procedure can be associated with a troublesome degree of pain that prevent some women from choosing its use. Different interventions have been described to decrease pain perception during intrauterine device insertion with no agreement on an effective one. Pre-insertion oral ibuprofen, diclofenac, nitroprusside, local anesthetics as lidocaine and prostaglandins has been reported with variable degrees of success .


Eligibility criteria: Inclusion criteria:

* Non-pregnant women
* Women that did not receive any analgesics or misoprostol in the 24 hours prior to insertion
* Women who delivered only by caesarean section

Exclusion criteria:

* Women with any uterine abnormalities as congenital anomalies, endometrial lesions, adenomyosis, fibroids
* Those with a Category 3 or 4 conditions for intrauterine device insertion according to the WHO Medical Eligibility Criteria for contraceptive use
* Allergy to lidocaine.
* Women refuse to participate in the study

Primary outcomes:
measure: The difference in pain scores during intrauterine device insertion
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University
Study officials:
References:
citation: Abbas AM, Abd Ellah NH, Hosny MA, Abdellah MS, Ali MK. Self-administrated vaginal 2% lidocaine in-situ gel for pain relief during copper intrauterine device insertion in women with previous caesarean delivery only: a randomised, double-blind placebo-controlled trial. Eur J Contracept Reprod Health Care. 2021 Apr;26(2):132-138. doi: 10.1080/13625187.2020.1868427. Epub 2021 Feb 4.
Clinical trial NCT05767411: Asymmetric Movement of the Diaphragm
Official title: The Effect of Asymmetric Postural Loading on the Movement of the Right Hemidiaphragm
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Lead sponsor: University Hospital, Motol
Sponsor class: OTHER
First posted: 2023-03-14
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy Subjects

Brief summary: The aim of this study is to investigate the movement of the right hemidiaphragm when lifting a load with the left and right hand.

Detailed description: Hemidiaphragm movement will be assessed by m-mode ultrasonography in a standing position. The study will include 30-40 healthy adult volunteers. The examination will consist of two tidal inspirations and expirations, two inspirations and expirations during lifting the kettlebell with the left hand and two inspirations and expirations during lifting the kettlebell with the right hand. The weight of the kettlebell will correspond to about 10% of the participant's body weight.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent form
* Able to comply with the study protocol, in the investigator's judgment
* Aged 18-40 years, inclusive
* Healthy as determined by the Investigator based on medical history, physical examination, vital signs and neurological examination
* Waist-to-height ratio \< 0,59

Exclusion Criteria:

* Low back pain (acute or chronic)
* Previous abdominal or spine surgery
* Acute or chronic respiratory or musculoskeletal disorder
* Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks before initiation of the study
* Pregnancy

Primary outcomes:
measure: Hemidiaphragm movement
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Prague
country: Czechia
facility: Pavel Kolar´s Centre of Physical Medicine
Study officials:
affiliation: Department of Rehabilitation and Sports Medicine, University Hospital Motol, Prague, Czech Republic
name: Pavel Kolar, Prof, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05381311: Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
Official title: Prospective Evaluation of Patient Preferences for Outcomes of Hormonal Agents and Chemotherapy in Combination With Androgen Deprivation Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer
Keywords: prostate cancer
metastatic hormone-sensitive prostate cancer
observational
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2022-05-19
Enrollment: 1020
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with mHSPC or locally-advanced prostate cancer with or without previous experience with ADT.

Brief summary: The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.

Detailed description: The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/surveys are being collected in: United States, Canada, UK, France, Spain, Japan, China and South Korea.

Eligibility criteria: Inclusion Criteria:

For interviews (attribute prioritization and pretest interviews)

* Diagnosis of mHSPC with or without previous experience with ADT
* Able to read and understand the survey language
* Able to provide informed consent For online survey
* Diagnosis of mHSPC or locally-advanced prostate cancer with or without previous experience with ADT
* Able to read and understand the survey language
* Able to provide informed consent

Exclusion Criteria:

Not applicable

Primary outcomes:
measure: Log-odds (preference weights) by participant cancer type and country
timeFrame: 1 day (once through survey)
Secondary outcomes:
measure: Relative importance weights by participant type and country
timeFrame: 1 day (once through survey)
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke Clinical Research Institute
state: North Carolina
Study officials:
affiliation: Astellas Pharma Global Development, Inc.
name: Astellas Pharma Global Development, Inc.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02158611: Whole Person Care Research Program of the Suicide Cases Consultative Services
Official title: Whole Person Care Research Program of the Suicide Cases Consultative Services
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Suicide
Keywords: Individual Counseling service
Group Counseling service
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2014-06-09
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This project aims to provide more treatment options to suicide patients to further enhance the holistic medical services in Far Eastern Memorial Hospital. It focuses on high-risk cases, especially those whose suicidal behaviors are triggered by interpersonal/or emotional problems because psychological counseling or interpersonal growth groups of services have been shown to be beneficial to this population.


Eligibility criteria: Inclusion Criteria:

* above 20 years old, survivors from suicide.

Exclusion Criteria:

* under 20 years old
* prisoner
* suffer from a serious illness
* foreigner/ can't speak Chinese
* the people who can't express themselves
* can not be interviewed in FEMH
* people with severe physical or psychological symptoms

Primary outcomes:
measure: patient's satisficaction questionaire
timeFrame: six weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New Taipei City
country: Taiwan
facility: Far Eastern Memorial Hospital
Study officials:
References:
Clinical trial NCT01542411: Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Recurrent Pregnancy Loss
Lead sponsor: Yazd Medical University
Sponsor class: OTHER
First posted: 2012-03-02
Enrollment: 520
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This project evaluated 520 women with unexplained recurrent miscarriage for four years. They had referred to recurrent abortion clinic of Yazd Reproductive sciences institute. Women with unexplained recurrent miscarriage included in this study

Brief summary: This study evaluated the effect of anticoagulant treatment on the live-birth rate in women with a history of at least two continuous unexplained miscarriages or thrombophilia. It also compared two methods of treatment with aspirin and aspirin plus heparin.


Eligibility criteria: Inclusion Criteria:

* unexplained recurrent miscarriage,
* women had previous venous or arterial thromboembolism or who were heterozygous or homozygous for mutations for FV Leiden G1691A, prothrombin gene G20210A (FII G20210A), and methyltetrahydrofolate reductase C677T (MTHFR C677T)

Exclusion Criteria:

* abnormal karyotypes of both partners,
* uterine and cervical anatomical disorders on pelvic ultrasonography or hysteroscopy,
* abnormal ovaries and abnormal endocrine tests.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Yazd
country: Iran, Islamic Republic of
facility: Research and Clinical Centre for Infertility
Study officials:
affiliation: Yazd Shahid Sadoughi Medical Sciences University and Health Services, Yazd, Iran
name: Tahere Jahaninejad, MSC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05313711: Photographic Rhinometry Following Derm/Mohs Surgery for Skin Cancers
Official title: Study of Use of 'Photographic Rhinometry' Following Derm and Mohs Micrographic Surgery for Skin Cancers: A Follow-up Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Skin Cancer
Lead sponsor: NHS Grampian
Sponsor class: OTHER_GOV
First posted: 2022-04-06
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 68 participants undergoing surgery for removal of Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC).

Brief summary: Dermatological surgeons and patients routinely notice alterations in nasal shape and size following surgery and reconstruction. There is no uniform approach to objectively measure these changes. Anthropometric measurements are routinely used in rhinoplasty to assess outcomes, but they are time consuming and have not been reported as being used by dermatological surgeons. Soft-tissue measurements in profile photographs have been demonstrated to be useful for objective measurement of nasal change following surgery. This is a follow up study of the pilot study to assess the feasibility of photographic rhinometry as an objective tool, and (ii) to quantify changes following common dermatological surgical procedures on the nose. This follow-up study will aim to recruit a larger population sample to better quantify some of the changes occurring post-operatively.


Eligibility criteria: Inclusion Criteria:

* Gender: Male and female participants
* Type of cancer: Undergoing surgery for removal of Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC))

Exclusion Criteria:

* Cases unable to consent to participation in the study
* Patients who are unable to complete the study assessments
* Patients below 18 years of age
* Patients undergoing surgery for other types of skin cancer

Primary outcomes:
measure: The primary outcome is to quantify changes following common dermatological surgical procedures on the nose.
timeFrame: "baseline, pre-intervention/procedure/surgery" and "immediately after the intervention/procedure/surgery"
Secondary outcomes:
Other outcomes:
Locations:
city: Aberdeen
country: United Kingdom
facility: Burnside House, Foresterhill Health Campus, Cornhill Road,
city: Uxbridge
country: United Kingdom
facility: The Hillingdon Hospitals NHS Foundation Trust
Study officials:
affiliation: NHS Grampian
name: Sanjay Rajpara, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06886711: Research on the Role of Probiotics in Human Intestinal Health
Official title: A Study on the Safety and Efectiveness of Bifidobacterium Bifidum BBi32 in Improving Lntestinal and Lmmune Functions
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Intestinal Microbiota
Keywords: Probiotics
Intestinal Barrier Function
Lead sponsor: Wecare Probiotics Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-03-20
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluate the efectiveness and safety of Bifidobacterium bifidum BBi32 as a food supplement compared to a placebo in improving intestinal andimmune functions in healthy adults.


Eligibility criteria: Inclusion Criteria:

1. Willing to attend 3 follow-up visits during the intervention period
2. Agree to provide blood, urine, and stool samples twice during the intervention period
3. Good eyesight, able to read and write, and capable of wearing glasses if needed
4. Good hearing and able to fully comprehend all instructions during the intervention

Exclusion Criteria:

1. Presence of digestive diseases, particularly gastrointestinal disorders (e.g., celiac disease, ulcerative colitis, Crohn's disease)
2. History of serious neurological conditions (e.g., epilepsy, stroke, severe head trauma, meningitis within the last 10 years, brain surgery, brain tumor, or prolonged coma-not including general anesthesia)
3. History of or currently receiving treatment for mental health disorders such as alcohol/drug/substance abuse, schizophrenia, psychosis, or bipolar disorder
4. Currently taking medication for depression or low mood
5. Presence of internal organ failure (e.g., heart, liver, or kidney failure)
6. History of radiation therapy or chemotherapy treatments
7. Underwent general anesthesia within the past three years or are scheduled for general anesthesia within the next 3 months during the trial period
8. History of hepatitis (B or C), HIV, or syphilis

Primary outcomes:
measure: Change in Fecal Microbiota Composition Before and After Intervention
timeFrame: Baseline (Week 0) and post-intervention (Week 8)
Secondary outcomes:
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Henan University of Technology
state: Henan
Study officials:
References:
Clinical trial NCT04340011: Colposcopy Education Using Operant Learning
Official title: Colposcopy Education Using Operant Learning
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Educational Problems
Cervix, Dysplasia
Keywords: colposcopy
resident education
Lead sponsor: University of Virginia
Sponsor class: OTHER
First posted: 2020-04-09
Enrollment: 250
Sex: FEMALE
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Females over the age of 21 undergoing clinically indicated coposcopy that are able to give informed consent

Brief summary: Images will be collected during routine colposcopy and paired with their pathology results to be used for resident education

Detailed description: Identifying information will be removed and operant learning techniques will be applied to better educate residents on colposcopy.

Eligibility criteria: Inclusion Criteria:

* ability to give informed consent
* age 21or older
* undergoing clinically indicated colposcopy

Exclusion Criteria:

* under 21 years of age

Primary outcomes:
measure: Resident accuracy in identifying sites for biopsy during Colposcopy
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Charlottesville
country: United States
facility: Univeristy of Virginia
state: Virginia
Study officials:
affiliation: University of Virginia
name: Leigh Cantrell, MD
role: PRINCIPAL_INVESTIGATOR
References: